Innovative Solutions for Diagnostic Imaging QA, Nuclear Medicine, & Medical Imaging Tables Also Featured for Mirion Medical at RSNA
The new Instadose VUE advanced, wireless personal dosimeter offers a display screen for improved user engagement, insights, and compliance. (Credit: CDC on Unsplash)
Mirion, announced today that it will debut the new Instadose VUE personal dosimeter, from its Dosimetry Services brand, at the 2023 Radiological Society of North America (RSNA) Meeting starting Sunday in Chicago, Illinois.
Mirion Dosimetry Services joins Sun Nuclear, Capintec, and Biodex medical imaging brands in the Mirion Medical booth (#6328) at RSNA, which will feature products and services for occupational dosimetry, diagnostic imaging QA, nuclear medicine, and medical imaging tables and accessories.
Introducing the InstadoseVUE Personal Dosimeter
The new Instadose VUE advanced, wireless personal dosimeter offers a display screen for improved user engagement, insights, and compliance. Harnessing Bluetooth Low Energy Technology, the InstadoseVUE dosimeter enables wearers to capture personalized dose reads on-demand, anytime and anywhere.
With programmable calendar features, scheduling automatic dose reads ahead of time is easy, simplifying dose reporting and management even further.
ec² Software Solutions, Now Part of Mirion Medical
Earlier this month, Mirion Medical welcomed ec² Software Solutions, expanding the company’s Nuclear Medicine and Molecular Imaging Portfolio. Featured for ec² at RSNA in booth #2101, Numa software provides innovative DICOM and HL7 workflow and communications solutions to meet the specific needs of nuclear medicine, nuclear cardiology, Radiopharmacies, PET and PET/CT departments.
“We are thrilled to welcome ec² Software Solutions to our medical family of solutions, further expanding and strengthening our commitment to leverage ionizing radiation to support innovation in healthcare. By adding to our portfolio through acquisitions and strengthening our proven technologies, as we’ve done with our new InstadoseVUE dosimeter, we continue to build on the depth and breadth of our medical portfolio,” said Thomas Logan, Mirion CEO.
Source: Company Press Release